According to the speaker, which statement best reflects outcomes with newer frontline combinations in advanced-stage Hodgkin lymphoma?
Brentuximab vedotin- and nivolumab-AVD-based combinations keep more than 90% of patients in long-term remission, so the focus has shifted to choosing a regimen that minimizes long-term toxicity.
Despite brentuximab vedotin- and nivolumab-based combinations, about one-third of advanced-stage patients still relapse, so consolidative radiotherapy is now routinely recommended.
Rituximab-ABVD has become the preferred frontline regimen, with long-term remission rates of about 75%.